Targeting the cancer kinome through polypharmacology.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20094047.
- Also identified by DOI 10.1038/nrc2787 and PMC identifier 2880454.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.
Medical subject headings
- Antineoplastic Agents
- Drug Delivery Systems
- Drug Discovery
- Drug Resistance, Neoplasm
- Neoplasms
- Protein Kinase Inhibitors